NCT00559754View on ClinicalTrials.gov

A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

Breast Cancer

Interventions

DRUG

bevacizumab [Avastin]

15mg/kg iv on day 1 of each 3 week cycle

DRUG

Docetaxel

75mg/m2 iv on day 1 of each 3 week cycle

DRUG

Standard chemotherapy

As prescribed

Trial Locations (6)

14004

Córdoba

23007

Jaén

25198

Lleida

29010

Málaga

50009

Zaragoza

08208

Sabadell, Barcelona

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT00559754 - A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer. | Biotech Hunter | Biotech Hunter